Abstract
N-(DL-seryl)-N′-(2,3,4-trihydroxybenzyl)-hydrazine (HCl) (Ro 4-4602) is a strong inhibitor of decarboxylase of aromatic amino-acids in vivo and in vitro1,2. The drug counteracts the increase of 5-hydroxytryptamine which is induced by 5-hydroxytryptophan less markedly in the brain than in extracerebral organs. Small doses of Ro 4-4602 have even seemed to enhance this transformation in the brain; this effect could not be explained3,4.
Similar content being viewed by others
References
Burkard, W. P., Gey, K. F., and Pletscher, A., Experientia, 18, 411 (1962).
Burkard, W. P., Gey, K. F., and Pletscher, A., Arch. Biochem., 107, 187 (1964).
Pletscher, A., and Gey, K. F., Biochem. Pharmacol., 12, 223 (1963).
Kunz, E., Arch. Intern. Pharmacodyn., 142, 1 (1964).
Anton, A. H., and Sayre, D. F., J. Pharmacol . Exp. Therap., 138, 360 (1962).
Bertler, A., Carlsson, A., and Rosengren, E., Acta Physiol. Scand., 44, 273 (1958).
Goldstein, M., Intern. J. Neuropharmacol., 3, 37 (1964).
Udenfriend, S., Zalzman-Nirenberg, P., Gordon, R., and Spector, S., Mol. Pharmacol., 2, 95 (1966).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
BARTHOLINI, G., BURKARD, W., PLETSCHER, A. et al. Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase. Nature 215, 852–853 (1967). https://doi.org/10.1038/215852b0
Received:
Issue Date:
DOI: https://doi.org/10.1038/215852b0
- Springer Nature Limited
This article is cited by
-
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease
npj Parkinson's Disease (2023)
-
L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
Journal of Neural Transmission (2023)
-
Brain-restricted mTOR inhibition with binary pharmacology
Nature (2022)
-
Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment
Journal of Neurology (2022)
-
Aspartate/asparagine-β-hydroxylase: a high-throughput mass spectrometric assay for discovery of small molecule inhibitors
Scientific Reports (2020)